my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
22-05-2012: Prosonix announced the second closing of its Series B equity financing round. In extending the financing round to £17.1M, the Company raised an additional £5.7M from new investor Gimv, a leading European technology investor, as well as from the syndicate of investors that participated in the first closing of the round in June 2011. The syndicate includes Ventech (Paris, France), Gilde Healthcare Partners (Utrecht, Netherlands), Entrepreneurs Fund (London, UK), Quest for Growth (Leuven, Belgium) and Solon Ventures (London, UK).
Dr Karl Nägler, a Venture Capital Partner at Gimv, will also join the Prosonix board as a Non-executive Director.
The proceeds of the financing will be used to progress the Company’s emerging proprietary product pipeline of excipient-free, drug-only inhalable mono- and combination therapies. Prosonix applies its proprietary ultrasonic particle engineering technology to existing drug compounds in low-cost generic devices, utilising where possible the new regulatory guidelines for accelerated approval.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Prosonix has received a grant worth up to £1.3M from the Biomedical Catalyst. The grant will provide matched-funding support for the pre-clinical development of the Company’s Multi-component particle™ (MCP™) platform as a basis for future combination respiratory medicines. The £180M Biomedi ... more
Prosonix Elects Dr Ken Cunningham as Non-executive Chairman
Prosonix announced the election of Dr Ken Cunningham as Non-executive Chairman. He replaces Dr Jim Philips, who has been Chairman of the Company since 2007, and is retiring from the Board of Directors.Dr Cunningham was elected to the Board of Prosonix as a Non-executive Director in Septembe ... more
Prosonix Extends Series B Financing Round to £17.1M
Prosonix announced the second closing of its Series B equity financing round. In extending the financing round to £17.1M, the Company raised an additional £5.7M from new investor Gimv, a leading European technology investor, as well as from the syndicate of investors that participated in t ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
